Global Non-Oncology Precision Medicine Market by Ecosystem (Applied Sciences, Precision Diagnostics, Digital Health and Information Technology, Precision Therapeutics), By Application (Infectious diseases, Neurology, Endocrinology, Cardiovascular, Others), and by Regions (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) Global Forecasts 2017-2027

Market Overview: 

The Global Non-Oncology Precision Medicine Market was valued at USD 45.0 billion in 2020, and it is expected to reach USD 130.2 billion by 2027, with a CAGR of 16.4%, during the forecast period from 2021-2027.

Precision medicine is an approach to patient care that is based upon the idea that a condition of patient suffering with cancer, immunodeficiency disorder, or any genetic disorder is not necessarily the same in someone else who has that condition. The genes inherited form generations and the environment where one lives can influence one’s health and symptoms. Thus, treatment may vary from individual to individual. Precision medicines attempts to understand how variations in patient's genes influence health.  Mostly precision medicine is used for cancer treatments. However, advances in research and technologies, precision medicines are now a days used to treat different diseases and disorders.

Rising number of incidences of infectious and respiratory diseases, ability to provide personalized treatment, and investment by market players are some of the major driving factors of the non-oncological precision medicine market. For instance, since past four years (2016- 2020), the market witnessed approximately four funding and investments, 59 collaborations and partnerships, 44 product launches and enhancements, 18 mergers and acquisitions, 26 regulatory and legal activities, and six business expansions.

Non-Oncology Precision Medicine Market

The Global Non-Oncology Precision Medicine Market Segmentation:

  • By Ecosystem Type
    • Applied Sciences
    •  Precision Diagnostics
    • Digital Health & Information Technology
    • Precision Therapeutics
  • By Application
    • Infectious Diseases
    • Neurology
    • Endocrinology
    • Cardiovascular
    • Others
  • By Geographical Region
    • North America
    • Europe
    • Asia- Pacific
    • South America
    • Middle East & Africa

Based on ecosystem type, applied sciences segment held the largest share in 2020.

The global non-oncology precision medicine market (by ecosystem) is segmented into applied sciences, precision therapeutics, digital health and information technology, and precision diagnostics. Applied sciences accounted for the largest share of the market and is expected to hold it’s share during the forecast period. Scientific discovery and technological advancement will continue to accelerate personalized medicine and offer exciting prospects to both corporations and patients.

Based on application type, Infectious disease is projected to hold highest market share during the forecast period.

Non-oncology precision medicines market is broadly segmented on basis of application such as infectious diseases, cardiovascular, neurological and others. Infectious disease segment accounted for the maximum share of the market. The COVID-19 pandemic itself caused more than half a million deaths by August 2020. The spiking number of incidences of infectious disease globally has made governments worldwide increasingly adopt precise diagnostic and treatment methods to tackle the ever-increasing disease burden.

Geographically, North America held the largest share of the market in 2020.

Geographically, North America is expected to hold maximum market share of non-oncology precision medicine market. Presence of advanced technology, increase in diseases patient population, and sophisticated healthcare infrastructure are some of the major factors for the dominance of the region across the world.

The Asia-Pacific region has been witnessing tremendous growth in precision medicine technology. APAC is home to several developing countries, such as China, India, Japan, and Australia, which are rapidly innovating and researching for precision medicine solutions to cater to better patient care.

The report also provides in-depth analysis of the Non-Oncology Precision Medicine Market dynamics such as drivers, restraints opportunities and challenges


  • Increased in availability of targeted therapies and reduction in trial and error-based prescription
  • Reduced Chances of Adverse Drug Reactions
  • Decreasing Overall Cost of The Genome Sequencing
  • Increasing Prevalence of Chronic Diseases


  • Lesser-known Treatment for Other Diseases Than Cancer
  • Unclear Framework About Regulatory Aspects of Personalized Medicines


  • Research and Development Across Industry Gear Up the Market Entry
  • Strong Product Pipeline
  •  Increasing FDA Approvals


  • Lack of Complete Knowledge Regarding Molecular Mechanism/Interaction
  • Integration of Electronic Health Record

COVID-19 Impact on the Non-Oncology Precision Medicine Market Analysis

Covid-19 has highly affected the industries in terms of growth, economy, health, and mental wellbeing of every individual. In this challenging situation, every industry is trying to give best services in terms of quality and safety.  Healthcare sector has highly affected by covid outbreak. However, the precision medicine has not much affected due to coronavirus.  This uncertain outbreak of coronavirus has led increase in demand for technology advances, transformation, and adaptability of non-oncology precision medicine. Rapid increase in respiratory diseases has led to increase in growth proliferating factor for non-oncology precision medicine as an immediate need for accurate drug treatment. Coronavirus has brought new light on non-oncology precision medicine market.

Covid does not had direct impact on precision medicines but provided an opportunity for the development of non-oncological precision medicines for other diseases like infectious, cardiovascular etc, which stood to be post covid treatment.

The report also provides in-depth analysis of key trends in Non-Oncology Precision Medicine market

Sr. No.




Due to Covid-19, there has been an opportunity for the use of non-oncology precision medicines for respiratory disease.  



Research alliance across industry and academia


The report also provides in-depth analysis of recent news developments and investments

  • In June 2021, Weill Cornell Medicine announced “We’re Changing Medicine” campaign worth USD 1.5 billion, which aims to advance biomedical innovations in areas such as artificial intelligence, precision medicine, machine learning, and genomics.
  • In June 2020, Infosys introduced SAP-based Personalized Medicine Solution for Pharma Companies. It uses blockchain, analytics, and IoT to address supply chain, patient management, and regulatory compliance.

Company Profiles and Competitive Intelligence 

The key players operating in the Non-Oncology Precision Medicine Market are:

  1. Abbott Laboratories
  2.  Agilent Technologies
  3. Asuragen
  4. Partek Incorporated
  5. Almac Group
  6. Bristol Myers Squibb
  7. bioMérieux SA
  8.  Bio-Rad Laboratories, Inc
  9.  Danaher Corp.
  10.  GlaxoSmithKline plc.
  11.  AstraZeneca PLC
  12.  Invitae Corporation
  13. Opko Health, Inc.
  14. Laboratory Corporation of America Holdings
  15. Pacific Biosciences of California, Inc.

The unique insights provided by this report also includes the following:

  • In-depth value chain analysis
  • Opportunity mapping
  • Sector snapshot
  • Key Players Positioning Matrix
  • Regulatory scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market trends
  • Covid-19 impact analysis
  • Product comparison
  • Pre & Post COVID 19 impacts on the non-oncology precision medicine market
  • Competitive Landscape

Frequently Asked Questions (FAQs)

The global non-oncology precision medicine market was valued at US $ 45.0 Bn in 2020 and is anticipated to reach US$ 130.2 Bn by 2027

The non-oncology precision medicine market is estimated to grow at a compound annual growth rate (CAGR) of 16.4% during 2021-2027.

In the base year 2020, North America accounted for about 40.0% share in the non-oncology precision medicine market.

Few key players include, but not limit up to: Abbott Laboratories, Agilent Technologies, Inc., Asuragen, Inc., Partek Incorporated, Almac Group, Bristol Myers Squibb, bioMérieux SA., BGI, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, Danaher Corp., GlaxoSmithKline plc., AstraZeneca PLC, Gilead Sciences, Inc. Illumina, Inc., Invitae Corporation, Opko Health, Inc., Laboratory Corporation of America Holdings, Pacific Biosciences of California, Inc., andox Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics.

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

  1. Introduction
    1. Product Outline
    2. What is non-oncology Precision Medicine
    3. Different Types of Non-Oncology Precision Medicines
    4. Covid -19 Impact
    5. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
    6. Technology Overview
    7. Patent Analysis
  2. Regulatory Landscape for Non-Oncology Precision Medicines
    1. Regulations and Standards
  3. Non-Oncology Precision Medicines Market Pricing Analysis
    1. Price Analysis of Precision Medicine
  4. Non- Oncology Precision Medicine Market by Ecosystem
    1. Applied Sciences
    2. Precision Diagnostics
    3. Digital Health & Information Technology
    4. Precision Therapeutics
  5. Non-Oncology Precision Medicine Market by Applications
    1. Infectious diseases
    2. Neurology
    3. Endocrinology
    4. Cardiovascular
    5. Others
  6. Non- Oncology Precision Medicine Market by Region
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France 
      4. Spain
      5. Netherlands
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. Rest Of Asia Pacific
    4. Middle East and Africa
    5. South America
  7. Key Strategic Insights
  8. New Raw Material Sources
    1. New Applications
    2. Emerging Technologies
    3. Opportunity mapping
    4. Critical Success Factors
    5. Environmental Impact and sustainability issues
    6. Consumer preferences
  9. Key Market Trends / Recent Developments
  10. Competitive Scenario
    1.  Mergers and Acquisitions
    2. Investments
    3. Joint Ventures
    4. New Product Launches
    5. Ranking of Key Players
  11. Key Global Players
    1. Abbott Laboratories
    2. Agilent Technologies
    3. Asuragen
    4. Partek Incorporated
    5. Almac Group
    6. Bristol Myers Squibb
    7. bioMérieux SA
    8.  Bio-Rad Laboratories, Inc
    9.  Danaher Corp.
    10.  GlaxoSmithKline plc.
    11.  AstraZeneca PLC
    12. Invitae Corporation


Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization